Verona Pharma plc (NASDAQ: VRNA) today presented Phase 2a and pharmacokinetic data from two clinical trials evaluating its lead product ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE